MX2022010593A - Composiciones tópicas de diclofenaco y métodos. - Google Patents

Composiciones tópicas de diclofenaco y métodos.

Info

Publication number
MX2022010593A
MX2022010593A MX2022010593A MX2022010593A MX2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A MX 2022010593 A MX2022010593 A MX 2022010593A
Authority
MX
Mexico
Prior art keywords
methods
topical diclofenac
diclofenac compositions
compositions
topical
Prior art date
Application number
MX2022010593A
Other languages
English (en)
Inventor
Dario N R Carrara
Amaud Grenier
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2022010593A publication Critical patent/MX2022010593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en el presente documento composiciones farmacéuticas que comprenden diclofenaco y métodos terapéuticos para su uso eficaz mediante una administración de una vez al día.
MX2022010593A 2020-02-27 2021-02-25 Composiciones tópicas de diclofenaco y métodos. MX2022010593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982589P 2020-02-27 2020-02-27
PCT/NL2021/050125 WO2021172987A1 (en) 2020-02-27 2021-02-25 Topical diclofenac compositions and methods

Publications (1)

Publication Number Publication Date
MX2022010593A true MX2022010593A (es) 2022-12-13

Family

ID=74858737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010593A MX2022010593A (es) 2020-02-27 2021-02-25 Composiciones tópicas de diclofenaco y métodos.

Country Status (9)

Country Link
US (1) US20230157979A1 (es)
EP (1) EP4110320A1 (es)
JP (1) JP2023515539A (es)
CN (1) CN115279360A (es)
AU (1) AU2021228521A1 (es)
BR (1) BR112022016887A2 (es)
CA (1) CA3169241A1 (es)
MX (1) MX2022010593A (es)
WO (1) WO2021172987A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20120157536A1 (en) * 2010-12-20 2012-06-21 Polytherapeutics, Inc. Composition for transdermal administration of non-steroidal anti-flammatory drug
US9713590B2 (en) * 2011-07-28 2017-07-25 Cadila Healthcare Limited Method for treatment of pain and inflammation
EP3275466A1 (en) * 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
US20140113970A1 (en) * 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system
US9468618B2 (en) * 2014-12-12 2016-10-18 Lupin Atlantis Holdings Sa Topical pharmaceutical gel composition of diclofenac sodium

Also Published As

Publication number Publication date
AU2021228521A1 (en) 2022-10-13
JP2023515539A (ja) 2023-04-13
CN115279360A (zh) 2022-11-01
EP4110320A1 (en) 2023-01-04
US20230157979A1 (en) 2023-05-25
CA3169241A1 (en) 2021-09-02
BR112022016887A2 (pt) 2022-10-18
WO2021172987A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
PH12020500672A1 (en) Splicing modulators antibody-drug conjugates
WO2020236825A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
JOP20200260B1 (ar) مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020011295A (es) Tratamiento de dermatitis atopica.
NZ609727A (en) A combination composition comprising ibuprofen and paracetamol
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
EP4410295A3 (en) Use of vibegron to treat overactive bladder
EA202190171A1 (ru) Применение грамотрицательных видов для лечения атопического дерматита
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EA201591603A1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
MX2024004013A (es) Composiciones liquidas orales de enzalutamida.
ZA202308035B (en) Application of riluzole- and borneol-containing composition in preparation of medication for treating cerebrovascular diseases
ZA202305383B (en) Topical administration of 2- (diethylamino) ethyl 2- (4-isobutylphenyl) propionate for treatment of diseases
WO2019067768A3 (en) FIXED DOSE COMBINATION FORMULATIONS FOR THE TREATMENT OF PAIN